PlexPrime® Technology
PlexPrime® enables high-level multiplexing of single nucleotide polymorphisms (SNPs) and mutations, especially when they are closely clustered. Novel primers have been designed with a unique Insert sequence, that increase specificity and act as a bar code for each target. These primers combined with PlexZyme® technology, achieves multiplex mutation detection with high sensitivity.
Complex mutation detection is simplified with PlexPrime® and can help with a diverse range of applications — from determining antimicrobial resistance, to health screening, guiding oncology treatment, or informing pharmacogenomics.
PlexPrime® Technology — Precision Mutation Detection
Detect antibiotic resistance markers and wild-type sequences in a single test
PlexPrime® technology powers our ResistancePlus® product family, which detect resistance mutations alongside pathogen identification to guide clinicians toward treatments that will actually work. The result is Resistance Guided Therapy (RGT). Global pioneers in this space, SpeeDx commercialised the first molecular multiplexed test for M. genitalium AMR in 2016, ResistancePlus® MG.
What clinicians and researchers had to say about ResistancePlus® MG facilitated RGT [1]:
“achiev[e] high levels of microbial cure (up to 95%)
and low levels of de novo resistance”
“[RGT is] an essential strategy to preserve our current antimicrobials
in the context of increasing antimicrobial resistance”
Detect antibiotic resistance markers and wild-type sequences in a single test
PlexPrime® technology powers our STI AMR assays, which detect resistance mutations alongside pathogen identification. Global pioneers in this space, SpeeDx commercialised the first molecular multiplexed test for M. genitalium AMR in 2016, ResistancePlus® MG*. Since then, in certain regions, our ResistancePlus® product family* has been used to inform Resistance Guided Therapy (RGT).
What clinicians and researchers had to say about ResistancePlus® MG* facilitated RGT [1]:
“achiev[e] high levels of microbial cure (up to 95%)
and low levels of de novo resistance”
“[RGT is] an essential strategy to preserve our current antimicrobials
in the context of increasing antimicrobial resistance”
“The ResistancePlus® tests* from SpeeDx represent essential diagnostic tools to guide the clinicians in delivering the most appropriate treatment to their patients.”
Franck Catteau
President of Biosapientia.
Beyond Simple Detection — Understanding Resistance
PlexPrime® technology transforms molecular diagnostics
Detect Resistance in Real-Time
Identify antimicrobial resistance mutations in the same test that detects the pathogen—no need for sequential testing or culture-based methods.
Guide Therapy Immediately
Provide actionable resistance information at the point of diagnosis, enabling clinicians to prescribe the right antibiotic the first time.
Treatment Guidance
Our ResistancePlus® MG assay for M. genitalium has been demonstrated to increase cure rates from 48% to 95% by detecting macrolide resistance mutations [1,2].
Combat Antimicrobial Resistance
Reduce unnecessary antibiotic use and slow the spread of resistant pathogens by enabling targeted therapy based on genetic evidence.
Beyond Simple Detection — Understanding Resistance
PlexPrime® technology transforms molecular diagnostics
Detect Resistance in Real-Time
Identify antimicrobial resistance mutations in the same test that detects the pathogen—no need for sequential testing or culture-based methods.
Empower AMR Research
Utilize off-the-shelf PlexPrime®-powered assays to broaden your research or surveillance initiatives—or let SpeeDx partner with you to develop novel AMR applications.
Combat Antimicrobial Resistance with Genetic Evidence
Using powerful PlexPrime® assays from SpeeDx, produce data to help inform changes to unnecessary antibiotic use, and help slow the spread of resistant pathogens.
ResistancePlus® — PlexPrime® Technology in Clinical Practice
"Local AMR testing and surveillance as well as diagnostic tests for M. genitalium need to become routinely available and should ideally be supplemented with molecular detection of mutations that mediate macrolide resistance. Such assays will substantially improve patient management."
Prof. Jorgen Jensen
Statens Serum Institut, Denmark
"The ResistancePlus® GC test* is the first innovation in gonorrhea treatment in decades. With the continued spread of multi-drug gonorrhea, this test can make a real difference."
Dr. Jeffrey Klausner
Professor of Medicine and Public Health at David Geffen School of Medicine and Fielding School of Public Health, University of California, Los Angeles.
ResistancePlus® — PlexPrime® Technology in Practice
ResistancePlus®® MG*
(M. genitalium + Macrolide Resistance)
Detects M. genitalium and macrolide resistance-mediating mutations in a single test. Guides clinicians to effective treatments and has been demonstrated to increase cure rates from 48% to 95% [1,2].
IVDR, UKCA, TGA, Health Canada Approved
ResistancePlus®® MG*
(M. genitalium + Macrolide Resistance)
Detects M. genitalium and macrolide resistance-mediating mutations in a single test. Guides clinicians to effective treatments and has been demonstrated to increase cure rates from 48% to 95% [1,2].
IVDR, UKCA, TGA,
"Local AMR testing and surveillance as well as diagnostic tests for M. genitalium need to become routinely available and should ideally be supplemented with molecular detection of mutations that mediate macrolide resistance. Such assays will substantially improve patient management."
Prof. Jorgen Jensen
Statens Serum Institut, Denmark
"The ResistancePlus® GC test is the first innovation in gonorrhea treatment in decades. With the continued spread of multi-drug gonorrhea, this test can make a real difference."
Dr. Jeffrey Klausner
Professor of Medicine and Public Health at David
Geffen School of Medicine and Fielding School of
Public Health, University of California, Los Angeles.
Demonstrated in STIs with our ResistancePlus® tests [3,4]. Applicable for infectious diseases of interest to you.
Antimicrobial Resistance
Demonstrated in STIs with our ResistancePlus® tests [3,4]. Applicable for infectious diseases of interest to you.
Guiding Oncology Treatment
Demonstrated in STIs with our ResistancePlus® tests [3,4]. Applicable for infectious diseases of interest to you.
Informing Pharmacogenomics
Demonstrated in STIs with our ResistancePlus® tests [3,4]. Applicable for infectious diseases of interest to you.
Customize
Looking for High Performance SNP and Mutation Detection?
Regardless of complexity, PlexPrime® is the solution for your project:
Contact the Technology team?
SpeeDx offers the technology, expertise, and partnership models to accelerate your diagnostic success.
References:
1. Durukan et. Al. Clin Infect Dis. 2020 Sep 12;71(6):1461-1468
2. Read et. al. Clin Infect Dis. 2019 Feb 1;68(4):554-560
3. Tabrizi et. al. PLoS One. 2016 Jun 6;11(6):e0156740
4. Cotton et. al. Diagn Microbiol Infect Dis. 2021 Apr;99(4):115262
Footnotes:
*ResistancePlus® products are not available in all regions. For options within your region please reach out to our team today.
References:
1. Durukan et. Al. Clin Infect Dis. 2020 Sep 12;71(6):1461-1468
2. Read et. al. Clin Infect Dis. 2019 Feb 1;68(4):554-560
3. Tabrizi et. al. PLoS One. 2016 Jun 6;11(6):e0156740
4. Cotton et. al. Diagn Microbiol Infect Dis. 2021 Apr;99(4):115262